TherapeuticsMD (TXMD) investor relations material

Executive summary

• Transitioned to a pharmaceutical royalty company after divesting commercial operations in December 2022, now primarily collecting royalties from licensees.

• Main revenue sources are royalties from Mayne Pharma, Theramex, and Knight for licensed products in the U.S. and internationally.

• Reported net income from continuing operations of $50 thousand for Q3 2025, reversing a net loss of $567 thousand in Q3 2024.

• License revenue increased to $784 thousand, up $237 thousand year-over-year, mainly from the Mayne License Agreement.

• Continues to evaluate strategic alternatives, including potential mergers, acquisitions, or asset sales, with no set timetable for completion.

Financial highlights

• License revenue for Q3 2025 was $784K, up $237K year-over-year; nine-month revenue was $2.13M, up $1.04M.

• Net income for Q3 2025 was $152K, compared to a net loss of $609K in Q3 2024; nine-month net income was $50K, versus a loss of $2.43M year-over-year.

• Cash and cash equivalents as of September 30, 2025, totaled $7.1M.

• Total operating expenses were $1.65M, a 2.1% decrease year-over-year.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to legal uncertainties, potential adverse outcomes, and capital market conditions.

• May need to raise additional capital through equity or debt to fund operations until cash flow positive.

• Actively exploring a range of strategic alternatives, including business combinations and asset sales, but no assurance or timeline for any transaction.